Key Highlights

● Phathom began screening patients on September 29, 2026 in pHalcon-NERD-302, a randomized Phase 3 trial of as-needed VOQUEZNA 10 mg.

● The study plans to enroll about 500 adults with non-erosive GERD who report heartburn at least four days per week.

● Participants complete a four-week open-label run-in, then 24 weeks of 1:1 randomized treatment with VOQUEZNA 10 mg or placebo.

● The primary endpoint is the percentage of heartburn episodes with complete relief within two hours and sustained 24-hour relief.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) reported in a Form 8-K that it began screening patients on September 29, 2026 in pHalcon-NERD-302, a randomized Phase 3 trial testing VOQUEZNA 10 mg taken as needed in adults with non-erosive gastroesophageal reflux disease, or NERD. The company expects topline results in the first quarter of 2028. The report was filed under Item 8.01, Other Events, and was signed by Anne Marie Cook, the company's Chief Legal Officer.

Trial Design

The filing describes pHalcon-NERD-302 as a multicenter, randomized, double-blind, placebo-controlled Phase 3 study of VOQUEZNA 10 mg administered as needed. It plans to enroll approximately 500 adults with NERD who report heartburn at least four days per week, at roughly 80 sites in the United States. The requirement of heartburn on at least four days per week defines the population the company intends to study, and the filing gives no further eligibility criteria.

The protocol begins with a four-week open-label run-in, during which participants take VOQUEZNA 10 mg daily. This is followed by 24 weeks of randomized treatment. Participants are assigned 1:1 to take either VOQUEZNA 10 mg or placebo on an as-needed basis. Double-blind means neither the participants nor the investigators are meant to know which treatment each participant receives.

The filing states the primary endpoint as the percentage of heartburn episodes in which patients experience complete relief within two hours and sustained relief for 24 hours post-dosing, measured at Week 12. The endpoint is defined by episodes rather than by patients or by days. The 8-K does not list secondary endpoints, statistical plans or the criteria for success, and it does not give dosing instructions beyond the as-needed regimen.

Regulatory Intent and Reporting

According to the filing, if the study is successful, it is intended to support a potential regulatory submission seeking a label expansion for VOQUEZNA tablets for this treatment regimen. The wording is conditional. The 8-K does not say that the company has agreed to the design with regulators, does not state when a submission might be made, and does not say whether an approval would follow. Whether the study meets its endpoint will not be known until the topline results, which the company expects in the first quarter of 2028.

Item 8.01 is the section of Form 8-K that companies use to report events they consider important to security holders that are not covered by another item. Phathom used it here to announce that patient screening has started, which is a development milestone rather than a financial result. The filing describes the trial in terms of its design and expected timing and does not include results, because none exist yet. The filing frames the trial as intended to support a possible future label expansion for VOQUEZNA tablets.

What the Filing Does Not Say

The report is a short announcement of a trial start. It does not include financial information, cost estimates for the study or any change to the company's guidance. It does not state how the results of any earlier study informed the design of this one, and it does not describe enrollment timing, meaning how long the company expects screening and randomization to take. It does not identify the trial sites or the investigators.

First Quarter 2028 Topline Timeline for VOQUEZNA

The date in the filing is the first quarter of 2028, when Phathom expects topline results from pHalcon-NERD-302. Between now and then, the company's quarterly reports may include updates on enrollment progress, and the filing does not say how any change to the expected timing of results would be communicated. Interim updates, and whether the results will be presented at a medical meeting or published in a journal, are not addressed in the 8-K.